US Patent Issued to Novo Nordisk, Yale University on April 14 for "Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele" (Connecticut, Maryland, Massachusetts Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,773, issued on April 14, was assigned to Novo Nordisk A/S (Bagsvaerd, Denmark) and Yale University (New Haven, Conn.).

"Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele" was invented by Jeffrey Testani (Guilford, Conn.), Veena Rao (Cerby, Conn.), Rahul Kakkar (Weston, Mass.), Madhav N. Devalaraja (Acton, Mass.) and Chih-Hung Lo (Rockville, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Opti...